Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oruka Therapeutics's Enterprise Value is $93.26 Mil.
Oruka Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Mar. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Oruka Therapeutics's Enterprise Value is $93.26 Mil.
Oruka Therapeutics does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Mar. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Oruka Therapeutics's Enterprise Value is $93.26 Mil.
Oruka Therapeutics does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Mar. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's EV-to-Revenue at this moment.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Oruka Therapeutics's Enterprise Value is $93.26 Mil.
Oruka Therapeutics does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's EV-to-FCF at this moment.
Oruka Therapeutics Enterprise Value Historical Data
The historical data trend for Oruka Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Oruka Therapeutics Enterprise Value Chart
Oruka Therapeutics Annual Data
Trend
Dec24
Enterprise Value
-
Oruka Therapeutics Semi-Annual Data
Mar24
Enterprise Value
-
Competitive Comparison of Oruka Therapeutics's Enterprise Value
For the Biotechnology subindustry, Oruka Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oruka Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Oruka Therapeutics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Oruka Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oruka Therapeutics (NAS:ORKA) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Oruka Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Oruka Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ORKA has been successfully added to your